# Acumen Pharmaceuticals Q3 2026 Results

> Acumen Pharmaceuticals reports narrower loss than expected for Q3 2026.
- Title: Acumen Pharmaceuticals Q3 2026 Results | Shortify
- Summary: Acumen Pharmaceuticals reports narrower loss than expected for Q3 2026. Acumen Pharmaceuticals reported a narrower loss per share of $0.35 vs $0.39 estimate…
- Keywords: acumen pharmaceuticals, q3 2026, alzheimers therapeutics, net loss, eps, abos, Acumen, Pharmaceuticals, 2026, Results, Alphastreet - Earnings Decoded. Market Intelligence Delivered
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/acumen-pharmaceuticals-releases-q3-2026-financial-results
- Author: AlphaStreet Newsdesk
- Published: 2026-10-26T11:49:03+00:00
- Read time: 1 min
- Topics: acumen pharmaceuticals, q3 2026, alzheimers therapeutics, net loss, eps, abos
## Q3 2026 Financial Results
Acumen Pharmaceuticals reported a narrower-than-expected loss for Q3 2026, beating analyst estimates by 10.3%.
## Net Loss Details
The company recorded a net loss of $25.4M with a loss per share of $0.35, down 20.4% from Q3 2025.
## Analyst Sentiment
Wall Street analysts maintain a bullish stance with 5 buy ratings and 1 hold recommendation for Acumen's stock.
## Key takeaway

Acumen Pharmaceuticals reported a narrower loss per share of $0.35 vs $0.39 estimate for Q3 2026, showing improved efficiency in Alzheimer's drug development.